Literature DB >> 17916603

Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature.

Daniel G Nicastri1, John T Doucette, Tony E Godfrey, Steven J Hughes.   

Abstract

The clinical significance of micrometastasis of colorectal cancer (CRC) to regional lymph nodes remains controversial. In this review, we analyze publications that have evaluated the clinical significance of occult lymph node metastasis in CRC. An extensive literature search identified 19 publications that evaluated the clinical significance of micrometastatic CRC by various methods, including immunohistochemistry (IHC; n = 13) and reverse transcription-polymerase chain reaction (RT-PCR, n = 6). These studies were reviewed for methodology and findings. Significant limitations in methodology were identified, including inconsistent histological definitions of micrometastatic disease, poor sampling because of an inadequate number of lymph nodes or number of sections per lymph node analyzed, lack of conformity with respect to IHC antibody or RT-PCR marker, and inadequate power because of small sample size. Micrometastatic lymph node metastasis identified by RT-PCR was consistently found to be prognostically significant, but this was not true of micrometastatic disease identified by IHC. RT-PCR analysis of lymph nodes with specific markers can help identify pN0 (pathological-negative lymph node) CRC patients at increased risk for recurrence. The identification of occult disease by IHC techniques may also ultimately prove to be associated with worse outcome, but a number of inadequately powered studies have concluded conversely.

Entities:  

Mesh:

Year:  2007        PMID: 17916603      PMCID: PMC2049052          DOI: 10.2353/jmoldx.2007.070032

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  41 in total

1.  Prognostic significance of perirectal lymph node micrometastases in Dukes' B rectal carcinoma: an immunohistochemical study by CAM5.2.

Authors:  N Isaka; M Nozue; M Doy; K Fukao
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

2.  Cytokeratin immunostaining patterns of benign, reactive lymph nodes: applications for the evaluation of sentinel lymph node specimen.

Authors:  M D Linden; R J Zarbo
Journal:  Appl Immunohistochem Mol Morphol       Date:  2001-12

3.  Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer.

Authors:  K Yasuda; Y Adachi; N Shiraishi; K Yamaguchi; Y Hirabayashi; S Kitano
Journal:  Ann Surg Oncol       Date:  2001-05       Impact factor: 5.344

4.  Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients.

Authors:  Robert Rosenberg; Axel Hoos; James Mueller; Patricia Baier; Dominik Stricker; Martin Werner; Hjalmar Nekarda; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

Review 5.  American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.

Authors:  C Compton; C M Fenoglio-Preiser; N Pettigrew; L P Fielding
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

6.  Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry.

Authors:  Shingo Noura; Hirofumi Yamamoto; Tadashi Ohnishi; Norikazu Masuda; Takashi Matsumoto; Osamu Takayama; Hiroki Fukunaga; Yasuhiro Miyake; Masakazu Ikenaga; Masataka Ikeda; Mitsugu Sekimoto; Nariaki Matsuura; Morito Monden
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

7.  Lymph node micrometastases do not predict relapse in stage II colon cancer.

Authors:  J Tschmelitsch; D S Klimstra; A M Cohen
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

8.  Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers.

Authors:  Conor P Delaney; Ian C Lavery; Antonio Brenner; Jeffrey Hammel; Anthony J Senagore; Robert B Noone; Victor W Fazio
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

9.  Prognostic significance of occult metastases in colon cancer.

Authors:  Arend E H Merrie; André M van Rij; Elizabeth R Dennett; Lynne V Phillips; Kankatsu Yun; John L McCall
Journal:  Dis Colon Rectum       Date:  2003-02       Impact factor: 4.585

10.  Micrometastasis in regional lymph nodes of extirpated colorectal carcinoma: immunohistochemical study using anti-cytokeratin antibodies AE1/AE3.

Authors:  R T Palma; J Waisberg; S H Bromberg; A B Simão; A C Godoy
Journal:  Colorectal Dis       Date:  2003-03       Impact factor: 3.788

View more
  49 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

2.  Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Authors:  Terry Hyslop; David S Weinberg; Stephanie Schulz; Alan Barkun; Scott A Waldman
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 3.  Molecular staging individualizing cancer management.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-04-01       Impact factor: 3.454

4.  Sentinel Lymph Node Biopsy in Colon Cancer: an Institutional Experience.

Authors:  Naresh Kumar Saidha; Ritu Mehta; Munish Malhotra; A K Singh; Deepankar Kumar; Chandra Prakash Sharma
Journal:  Indian J Surg Oncol       Date:  2019-08-13

Review 5.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 6.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

7.  Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading.

Authors:  Valeria Barresi; Luca Reggiani Bonetti; Giovanni Branca; Carmela Di Gregorio; Maurizio Ponz de Leon; Giovanni Tuccari
Journal:  Virchows Arch       Date:  2012-10-24       Impact factor: 4.064

8.  Intranodal Mapping Using Carbon Dye Results in More Accurate Lymph Node Staging in Colon Cancer Patients.

Authors:  Benjamin Weixler; Rene Warschkow; Andreas Zettl; Hans-Martin Riehle; Ulrich Guller; Carsten T Viehl; Markus Zuber
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

9.  Previstage GCC test for staging patients with colorectal cancer.

Authors:  Alex Mejia; Scott A Waldmana
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

Review 10.  Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer.

Authors:  Marilyn R Carlson
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.